BeiGene(BGNE) - 2024 Q2 - Quarterly Results

Exhibit 99.1 BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates • Generated total revenues of $929 million, an increase of 56% from the prior-year period; reduced GAAP operating loss and achieved non-GAAP operating income • Strengthened hematology leadership with global BRUKINSA revenues of $637 million, an increase of 107% from the prioryear period; advanced pivotal programs for BCL2 inhibitor sonrotoclax and BTK-targeted degrader BGB ...